帕博利珠单抗(Pembrolizumab) - 药物靶点：PD-1_在研适应症：输卵管癌，非肌层浸润性膀胱肿瘤，卵巢上皮癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Lambrolizumab、Pembrolizumab (Genetical Recombination)、Pembrolizumab (genetical recombination) (JAN)

+ [12]

靶点

PD-1

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [13]

在研适应症

输卵管癌非肌层浸润性膀胱肿瘤卵巢上皮癌+ [323]

非在研适应症

肢端雀斑恶性黑色素瘤急性髓性白血病NPM1突变急性髓系白血病+ [122]

原研机构

Merck & Co., Inc.

在研机构

Merck Sharp & Dohme LLC

默沙东研发（中国）有限公司

Merck Sharp & Dohme Corp.

+ [16]

非在研机构

Merck Sharp & Dohme (Ireland) Ltd.

Turnstone Biologics Corp.

Viralytics Pty Ltd.

权益机构

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

最高研发阶段批准上市

首次获批日期

美国 (2014-09-04),

黑色素瘤

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、优先药物（PRIME） (欧盟)、孤儿药 (日本)、孤儿药 (澳大利亚)、突破性疗法 (中国)、优先审评 (澳大利亚)、优先审评 (美国)、附条件批准 (中国)、优先审评 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 93660H

来源: *****

Sequence Code 93670L

来源: *****

关联

2,732

项与帕博利珠单抗相关的临床试验

NCT04266730

/ Suspended临床1期

Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

开始日期2027-05-20

申办/合作机构

Lineberger Comprehensive Cancer Center

NCT07689240

/ Not yet recruiting临床3期IIT

Phase III Study of Adjuvant Pembrolizumab vs Active Surveillance After Nephrectomy in Patients With Non-Clear Cell Renal-Cell Carcinoma

This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after nephrectomy may be more effective than the usual active surveillance approach for improving time without disease in patients with non-clear cell renal cell cancer.

开始日期2027-02-10

申办/合作机构

National Cancer Institute

ACTRN12626000937314

/ Not yet recruiting临床2期IIT

IMPACT - A phase 2 study of IMmunotherapy with Pembrolizumab and sACituzumab Tirumotecan in pMMR recurrent or advanced endometrial cancer

开始日期2027-02-01

申办/合作机构-

100 项与帕博利珠单抗相关的临床结果

登录后查看更多信息

100 项与帕博利珠单抗相关的转化医学

登录后查看更多信息

100 项与帕博利珠单抗相关的专利（医药）

登录后查看更多信息

10,944

项与帕博利珠单抗相关的文献（医药）

2026-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

作者: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

2026-12-31·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

作者: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

2026-12-31·Human Vaccines & Immunotherapeutics

Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities

Review

作者: Zang, Qiwei ; Jia, Huijun ; Wei, Hongyu ; Gong, Yifan ; Zhao, Chengguang

Immunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.

18,320

项与帕博利珠单抗相关的新闻（医药）

2026-09-11

·BioSpace

Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet

iStock, PaperFox Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes. Caspian Therapeutics has arrived on the biopharma scene, bringing with it $50 million in starting funds, a potentially disease-modifying answer for diabetes and the backing of the industry’s biggest player in metabolic disease, Eli Lilly. Caspian was spun out from Kura Oncology specifically to advance an investigational menin inhibitor for diabetes, according to a Wednesday announcement. The $50 million funding will support initial clinical proof-of-concept assessments in this indication, as well as help push the drug, dubbed KO-7246, through investigational new drug (IND)-enabling development. Caspian will also use the money for a second menin blocker for diabetes and cardiometabolic conditions, though not much is known about this asset. The funding push was led by BVF Partners with participation from Kura, diabetes powerhouse Eli Lilly and others. Designed to be taken orally, KO-7246 is a next-generation small-molecule blocker of menin, a scaffold protein that, according to Caspian, helps control the multiplication of pancreatic beta cells. In excess, menin’s activity could impair the pancreas’s ability to produce insulin, resulting in diabetes. Available treatments for diabetes work by supplementing the body’s insulin levels or targeting excess sugar in the blood. Caspian claims it is taking a separate, disease-modifying approach with KO-7426, “increasing the number and function” of the beta cells. Indeed, the biotech on Wednesday pointed to animal studies that have shown improvements in glycemic control and insulin production after menin inhibition, underscoring the approach’s therapeutic potential for both type 1 and type 2 diabetes. Caspian plans to IND application for KO-7426 “as soon as practicable,” according the Wednesday release. Under the terms of the launch, Caspian will have its own masthead and be under an “intercompany services arrangement” with Kura, under which the spinoff will have access to its parent company’s R&D and corporate capabilities. Kura will retain around 50% ownership of Caspian and have board representation. Caspian is entering a competitive cardiometabolic market, going up against some of the industry’s heaviest hitters, including its own backer Eli Lilly. The giant from Indiana owns the powerhouse tirzepatide franchise, sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Across both of these brands, tirzepatide made $36.51 billion in 2025—a sales total that cleanly outpaced Merck’s mega-blockbuster immunotherapy Keytruda. Lilly also markets its newly launched weight loss pill Foundayo. Perhaps an under-appreciated leader in the diabetes arena is Sanofi, which in June won the FDA’s approval for Tzield as the first disease-modifying therapy for pediatric patients with stage 3 type 1 diabetes. The greenlight marked “the end of the beginning” of diabetes treatments, Michael Haller, chief of pediatric endocrinology at the University of Florida, told BioSpace in July . That first chapter was characterized by the exclusive use of insulin-based treatments, he explained. “Hopefully now these other drugs in the pipeline can achieve a similar regulatory approval process and allow us to use personalized approaches to figure out which therapies are going to work best for individual patients.” Diabetes Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape with innovative approaches—and experts say there’s room for all of them. July 20, 2026 · 7 min read · Michael Gibney Read more

上市批准

2026-09-11

·BioSpace

Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026 Financing led by RA Capital Management, joined by Canaan Partners, Forbion, and other investors Sept. 09, 2026 -- Solstice Oncology, a clinical-stage immuno-oncology company focused on treating cancer early, in the neoadjuvant setting, today announced its launch and $225 million Series A financing led by RA Capital Management and joined by Canaan Partners, Forbion and other investors. Solstice is advancing its lead candidate porustobart, a differentiated, second-generation, Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, across two clinical indications, one in microsatellite-stable (MSS) colon cancer and a second, undisclosed indication. Its Phase 2 trial is evaluating porustobart in combination with pembrolizumab in the neoadjuvant setting for the treatment of MSS clinical stage II-III colon cancer, the indication with the largest segment of colon cancer patients, which has yet to benefit from immunotherapy. "We believe the greatest opportunity in oncology lies in treating disease earlier, in the neoadjuvant setting, when the tumor is still present, the immune system is still intact, and disease hasn't yet hardened its resistance to treatment," said Caroline Loew, PhD, Chief Executive Officer of Solstice Oncology. "Treating patients early with an immuno-oncology combination therapy like the one we are evaluating in our Phase 2 trial could allow the immune response to act systemically, reaching micrometastatic disease well beyond the primary tumor, which is where we see the greatest opportunity to improve cure rates and long-term survival. Since founding the company in February, our team has moved with the speed and discipline this opportunity demands, filing and clearing an IND and now advancing directly into a Phase 2 trial, for which we anticipate data in the second half of 2027." Porustobart is a second-generation, Fc-enhanced CTLA-4 antibody designed to overcome multiple facets of immunosuppression through two mechanisms of action: CTLA-4 checkpoint blockade and regulatory T cell (Treg) depletion via antibody-dependent cellular cytotoxicity (ADCC). It is being developed to be administered in combination with anti-PD-(L)1 therapy. The two agents work synergistically: anti-PD-(L)1 reawakens T cells that have already recognized the tumor, while porustobart widens that response by releasing a second, independent brake on the immune system and depleting the immunosuppressive Tregs that shield tumors from attack. MSS colon cancer has historically been unresponsive to immunotherapy, but data across this new class of Fc-enhanced CTLA-4 molecules appears to have changed that, producing not just a signal, but a true clinical synergistic effect with PD(L)-1 blockade. Porustobart's engineered, heavy-chain-only structure also gives it a markedly shorter half-life than first-generation CTLA-4 antibodies (4-5 days vs. roughly 2-3 weeks for existing CTLA-4 antibodies), which Solstice believes will enable more flexible dosing, potentially reducing the frequency and duration of immune-related adverse events, a key limitation of first-generation CTLA-4 antibodies. While the company's lead indication for porustobart is MSS clinical stage II-III colon cancer, it believes porustobart's mechanism has the potential to be effective in the neoadjuvant setting across multiple tumor types. "Solstice brings together a compelling approach to treating patients with high unmet need in a potentially curative setting, a de-risked molecule that has already demonstrated activity in late-stage patients in Phase 1/2 studies, and a team with decades of drug development experience who have led multiple approved medicines from first-in-human trials through registration,” said Josh Resnick, MD, Partner at RA Capital. “The team has rapidly designed and advanced a Phase 2 trial to generate an early, credible read on efficacy, and the size of this financing and the strength of the syndicate reflect our conviction in the science, the strategy, and this team's ability to execute." "We know that neoadjuvant approaches have great potential across a number of tumor types, and I believe that could be true for porustobart in MSS colon cancer," said Jenny Seligmann, MRCP, PhD, Professor at the University of Leeds. "Pathologic response has become a recognized signal of long-term benefit in this setting, and a study designed around that endpoint gives us a fast, meaningful way to evaluate whether this approach can change outcomes for patients with MSS colon cancer." In a Phase 2 clinical study conducted by the Company’s licensor Harbour BioMed, porustobart in combination with tislelizumab (a PD-1 inhibitor) showed a 30% objective response rate (7 of 23 patients), with strong durability, in late-line MSS metastatic colorectal cancer patients without liver metastases. Median duration of response was 8.4 months. Porustobart was shown to have a favorable safety pro supports late-stage clinical development. Porustobart is a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, designed to overcome multiple facets of immunosuppression by having two mechanisms of action: CTLA-4 checkpoint blockade and regulatory T cell (Treg) depletion through ADCC. When given in combination with anti-PD(L)-1 therapy, the two agents are designed to work synergistically: anti-PD(L)-1 reawakens T cells that have already recognized the tumor, while porustobart widens that response by releasing a second, independent brake on the immune system and depleting the immunosuppressive regulatory T cells that shield tumors from attack. Porustobart's engineered, heavy-chain-only structure also gives it a markedly shorter half-life than first-generation CTLA-4 antibodies, which Solstice believes will support a more favorable tolerability pro early disease, where patients are otherwise well. Solstice believes porustobart could be effective in the neoadjuvant setting across multiple early-stage cancers. Porustobart plus a PD(L)-1 blocker has already shown meaningful clinical activity in a Phase 2 clinical study conducted by Harbour BioMed: a 30% objective response rate with 8.4-month median duration of response in late-line, heavily pretreated MSS colorectal cancer patients without liver metastases, and a favorable safety pro of later-stage development. Solstice Oncology is a clinical-stage immuno-oncology company built around the neoadjuvant treatment setting, the point in a patient's disease course where the company believes the opportunity to improve cure rates and long-term survival is greatest. Founded in February 2026, Solstice is led by a team with decades of experience building and advancing successful immunotherapy drugs in oncology. The company is advancing porustobart, a second-generation Fc-enhanced CTLA-4 antibody, across two clinical indications: a Phase 2 study in combination with pembrolizumab in the neoadjuvant setting for clinical stage II-III MSS colon cancer, and a second, undisclosed clinical indication. Solstice's initial investors include RA Capital, Canaan Partners, and Forbion. The content above comes from the network. if any infringement, please contact us to modify.

2026-09-10

·微信

芦康沙妥珠单抗治疗晚期子宫内膜癌I/II期研究结果入选2026 IGCS年会快速口头报告

2026年国际妇科癌症学会(IGCS)年会将于当地时间10月1日至10月3日在加拿大蒙特利尔举行。科伦博泰TROP2 ADC芦康沙妥珠单抗(sac-TMT)(佳泰莱®)用于晚期子宫内膜癌(EC)的一项I/II期临床研究(2870-001/KL264-01)结果入选快速口头报告，相关研究摘要全文已于当地时间2026年9月10日发布在IGCS官方网站（网址：https://cslide.ctimeetingtech.com/igcs26/attendee/confcal/show/session/25），核心内容概述如下：芦康沙妥珠单抗(sac-TMT)单药治疗铂类化疗后进展的晚期或转移性子宫内膜癌：一项I/II期临床研究(2870-001/KL264-01)结果形式：快速口头报告RO006 编号：ID 588 时间：当地时间10月2日11:18-11:24 研究共纳入158例既往接受铂类化疗后出现疾病进展的局部晚期不可切除或转移性EC患者(其中101例既往接受过≥2线治疗)，分别接受芦康沙妥珠单抗(sac-TMT) 4mg/kg或5 mg/kg每两周一次治疗。在4 mg/kg组(114例)中，中位随访时间为18.1个月；在5 mg/kg组(44例)中，中位随访时间为28.1个月。截至2025年11月30日，研究结果显示：经确认的总人群的ORR为32.3%，其中4 mg/kg组及5 mg/kg组分别为31.6%，34.1%；总人群的DOR为11.8个月，PFS为6.4个月，OS为17.6个月；其中4mg/kg组分别为12.4个月、6.0个月及16.8个月，5mg/kg组分别为8.7个月、7.3个月及18.1个月。安全性方面，截至数据截止日期，4 mg/kg组和5 mg/kg组分别有21.1%和4.5%患者仍在治疗中；另有58.8%和75.0%患者因疾病进展停药。总人群中发生≥3级治疗相关不良事件(TRAE)的比例为60.1%，其中4mg/kg组及5mg/kg组分别为53.5%、77.3%。最常见的不良事件为血液学毒性及口腔炎。此项研究结果表明：芦康沙妥珠单抗(sac-TMT)在铂类化疗进展后的晚期或转移性EC中显示出有前景的抗肿瘤活性与可控的安全性。这一结果为正在开展的sac-TMT治疗晚期EC的全球III期临床研究提供了有力支持——包括用于铂类化疗及免疫治疗进展后的晚期EC的TroFuse-005研究(NCT06132958)，以及联合帕博利珠单抗用于错配修复功能完整(pMMR)EC一线维持治疗的TroFuse-033研究(NCT06952504)。值得一提的是，此前TroFuse-005研究已顺利达到OS与PFS双主要终点，使芦康沙妥珠单抗(sac-TMT)成为了EC二线及以上治疗领域首个且唯一实现该双主要终点突破的ADC。关于芦康沙妥珠单抗(sac-TMT)(佳泰莱®) 芦康沙妥珠单抗(sac-TMT)是一款科伦博泰拥有自主知识产权的新型TROP2 ADC，针对非小细胞肺癌(NSCLC)、乳腺癌(BC)、胃癌(GC)、妇科肿瘤及泌尿生殖系统肿瘤等晚期实体瘤。截至目前，芦康沙妥珠单抗(sac-TMT)的4项适应症已于中国获批上市，分别用于：1)既往至少接受过2种系统治疗（其中至少1种治疗针对晚期或转移性阶段）的不可切除的局部晚期或转移性三阴性乳腺癌(TNBC)；2)经表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)和含铂化疗治疗后进展的表皮生长因子受体(EGFR)基因突变阳性的局部晚期或转移性非鳞状NSCLC；3)经EGFR-TKI治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状NSCLC；4)既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体阳性(HR+)且人类表皮生长因子受体2阴性(HER2-) (免疫组织化学(IHC) 0、IHC 1+或IHC 2+/原位杂交(ISH)-)BC；其中前2项适应症已经被纳入医保范围，将为更多乳腺癌和非小细胞肺癌患者带来临床获益。此外，芦康沙妥珠单抗(sac-TMT)已获国家药品监督管理局(NMPA)授予6项突破性疗法认定(BTD)。芦康沙妥珠单抗(sac-TMT)是全球首个在肺癌适应症获批上市的TROP2 ADC药物。2022年5月，科伦博泰授予默沙东(美国新泽西州罗威市默克公司的商号)在大中华区(包括中国内地、香港、澳门及台湾)以外的所有地区开发、使用、制造及商业化芦康沙妥珠单抗(sac-TMT)的独家权利。目前，科伦博泰已在中国开展9项注册性临床研究。默沙东已启动17项正在进行的芦康沙妥珠单抗(sac-TMT)作为单药疗法或联合帕博利珠单抗或其他抗癌药物用于多种类型癌症的全球性III期临床研究(这些研究由默沙东申办并主导)。

抗体药物偶联物临床结果临床3期临床2期临床成功

100 项与帕博利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10574	帕博利珠单抗	L01XC18	DB09037

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
输卵管癌	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
非肌层浸润性膀胱肿瘤	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
卵巢上皮癌	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
原发性腹膜癌	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
浸润性膀胱癌	欧盟	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	冰岛	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	列支敦士登	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	挪威	Merck Sharp & Dohme BV	2026-07-01
铂耐药性输卵管癌	中国	Merck Sharp & Dohme LLC	2026-06-23
铂类耐药性原发性腹膜癌	欧盟	Merck Sharp & Dohme BV	2026-04-22
铂类耐药性原发性腹膜癌	冰岛	Merck Sharp & Dohme BV	2026-04-22
铂类耐药性原发性腹膜癌	列支敦士登	Merck Sharp & Dohme BV	2026-04-22
铂类耐药性原发性腹膜癌	挪威	Merck Sharp & Dohme BV	2026-04-22
铂耐药上皮性卵巢癌	欧盟	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	冰岛	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	列支敦士登	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	挪威	Merck & Co., Inc.	2026-04-02
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme Corp.	2026-02-10
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肿瘤	美国	Merck Sharp & Dohme Corp.	2026-02-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性铂耐药性卵巢癌	申请上市	美国	Merck & Co., Inc.	2025-10-20
小肠癌	申请上市	欧盟	Merck Sharp & Dohme Corp.	2022-03-25
非小细胞肺癌Ⅰ期	临床3期	美国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	加拿大	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	法国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	德国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	希腊	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	匈牙利	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	以色列	Merck Sharp & Dohme LLC	2026-05-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02617849 (Pubmed \| Oncoimmunology)	临床2期	黑色素瘤	30	Pembrolizumab and Carboplatin/ Paclitaxel	糧廠餘壓製構壓製鬱簾(網憲鏇衊襯鹽鏇衊鏇網) = 窪餘鬱積壓選鑰鏇鬱網膚壓鬱糧構鏇齋淵鏇膚 (壓衊簾衊範齋鬱繭憲獵 ) 更多	不佳	2026-12-31
KEYNOTE-024 (WCLC2026)	N/A	非小细胞肺癌 PD-L1	369	Pembrolizumab-based treatment (Completion group)	淵繭蓋廠糧獵鏇鏇範網(築觸遞鏇憲夢淵遞範齋) = 選淵艱餘鹹鹹憲構鑰構鑰醖積選壓積願齋鹹鏇 (簾遞壓淵齋餘齋襯構製 ) 更多	积极	2026-09-12
				Pembrolizumab-based treatment (Discontinuation group)	淵繭蓋廠糧獵鏇鏇範網(築觸遞鏇憲夢淵遞範齋) = 糧顧衊積積獵壓壓製蓋鑰醖積選壓積願齋鹹鏇 (簾遞壓淵齋餘齋襯構製 ) 更多
KEYNOTE-189 (WCLC2026)	临床3期	转移性非小细胞肺癌一线	1,175	Pembrolizumab plus chemotherapy	憲範網遞齋構憲構鑰遞(觸餘遞襯夢積鹹遞艱選) = 顧蓋醖窪鹹淵鬱壓憲鑰構積夢製觸積艱衊願蓋 (築淵鹹鹽膚範遞獵衊憲, 12.7 ~ 20.0)	积极	2026-09-12
				Chemotherapy	憲範網遞齋構憲構鑰遞(觸餘遞襯夢積鹹遞艱選) = 鏇積顧網獵鑰餘糧築鹹構積夢製觸積艱衊願蓋 (築淵鹹鹽膚範遞獵衊憲, 3.3 ~ 10.3)
WCLC2026	N/A	非小细胞肺癌新辅助	110	Neoadjuvant regimens included tislelizumab/pembrolizumab/mixed	繭衊鹹艱構蓋築積膚觸(窪醖製鏇積餘鹽鏇淵顧) = 鹹夢齋遞淵鹹構簾鑰顧糧餘鏇膚網鏇鹹簾範膚 (遞窪艱餘簾餘襯鑰鹽窪 ) 更多	积极	2026-09-12
WCLC2026	N/A	鳞状非小细胞肺癌一线	82	carboplatin+ paclitaxel+ pembrolizumab	構淵淵窪蓋蓋窪顧齋壓(鏇遞淵範選膚網網衊艱) = 壓膚蓋夢鏇繭壓選鹽構餘醖廠鏇顧壓廠製鏇繭 (製積觸願齋膚衊艱鹽壓, 11.4 ~ 23.0) 更多	积极	2026-09-12
				pembrolizumab	構淵淵窪蓋蓋窪顧齋壓(鏇遞淵範選膚網網衊艱) = 膚製壓範願鏇淵膚簾膚餘醖廠鏇顧壓廠製鏇繭 (製積觸願齋膚衊艱鹽壓, 14.3 ~ 23.2) 更多
NCT03654833 (MIST3, WCLC2026)	临床2期	间皮瘤 NF2 loss \| ETS family inhibitor NAB2	21	Bemcentinib and pembrolizumab	艱鬱繭遞遞衊積膚艱醖(鹹構鑰醖願衊齋糧網願) = 願襯範鑰築夢積艱衊遞鹹範積憲觸鬱憲憲壓遞 (齋鑰網簾選衊艱夢襯憲, 29.2 ~ 63.8) 更多	积极	2026-09-12
WCLC2026	N/A	转移性非小细胞肺癌一线	157	pembrolizumab plus platinum‐based chemotherapy (Early ToDA)	鑰夢廠製鑰繭窪顧醖蓋(繭簾醖齋簾積築範遞齋) = 衊鹽憲壓廠夢襯夢築築範選簾膚觸鏇膚壓壓範 (鹹繭繭遞獵廠製壓憲積 ) 更多	积极	2026-09-12
				pembrolizumab plus platinum‐based chemotherapy (Late ToDA)	鑰夢廠製鑰繭窪顧醖蓋(繭簾醖齋簾積築範遞齋) = 鹹選範襯淵膚鏇餘遞廠範選簾膚觸鏇膚壓壓範 (鹹繭繭遞獵廠製壓憲積 ) 更多
WCLC2026	N/A	MET基因扩增非小细胞肺癌一线 MET Amplification \| PD-L1 Expression	4	savolitinib	鹽觸壓選窪齋積鹹簾壓(憲醖顧齋選淵艱鑰構夢) = 淵餘齋壓壓製鏇遞願襯壓範積範鏇餘製範積鏇 (蓋餘鏇選膚願淵願壓繭 )	积极	2026-09-12
				carboplatinnab-paclitaxel + carboplatinnab-paclitaxel + carboplatinnab-paclitaxel	鹽觸壓選窪齋積鹹簾壓(憲醖顧齋選淵艱鑰構夢) = 鬱齋觸膚選構夢選鏇選壓範積範鏇餘製範積鏇 (蓋餘鏇選膚願淵願壓繭 )
NCT04907851 (WCLC2026)	临床1/2期	非小细胞肺癌	32	Tulmimetostat 200 mg	製鹹獵衊艱顧構鹹齋遞(築顧顧獵願觸襯夢顧壓) = 300 mg 製鏇選淵獵窪選餘網齋 (衊襯鬱遞積鹽鑰繭廠糧 )	积极	2026-09-12
				Tulmimetostat 300 mg
NCT06155279 (CHIMERA, WCLC2026)	临床2期	恶性胸膜间皮瘤新辅助	41	Pembrolizumab plus pemetrexed and cisplatin or carboplatin	鹹鹹夢鬱範積網憲鹽遞(膚鏇積觸襯糧鏇淵顧餘) = 鏇艱鹹壓築簾餘襯觸鹹襯淵廠簾廠簾壓餘膚繭 (鹹製襯憲範網鬱窪壓顧 ) 更多	不佳	2026-09-12